Oncology Medical News about Myelogenous Leukemia

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Quantifying the Survival Benefit for Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed Acute Myelogenous Leukemia
Biology of Blood and Marrow Transplantation, 09/16/09

Armistead PM et al. – Allogeneic hematopoietic stem cell transplantation (HSCT) is the recommended therapy for patients with relapsed acute myelogenous leukemia (AML), despite little evidence showing a survival benefit in patients who undergo HSCT versus chemotherapy alone. HSCT is preferable to chemotherapy alone in these patients with poor prognoses, with particular benefits noted in patients under age 50 years.

<< Previous
Decision Analysis of Peripheral Blood versus Bone Marrow...

Next >>
Busulfan and Cyclophosphamide (Bu/Cy) as a Preparative Regimen...

A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
Clinical Cancer Research, 10/26/09 Relevance Score: 66%

Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro
Cancer Research, 10/05/09 Relevance Score: 66%

Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia
Blood, 11/13/09 Relevance Score: 65%

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib
Blood, 11/09/09 Relevance Score: 65%

Suboptimal Responses to Imatinib in Chronic Myelogenous Leukemia
Clinical Journal of Oncology Nursing, 10/08/09 Relevance Score: 65%